Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Results of Shareholders’ Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Date of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Acquires DMT Clinical Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.